Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of March 31, 2026)

  • $116M

    TTM
    Revenue

  • $10M

    TTM Adjusted EBITDA

  • $41M

    Cash balance
    with no debt

  • #1

    OA Pain
    U.S. Market Share

    ~25M

    Injections
    Worldwide

Recent News
Anika Reports First Quarter 2026 Financial Results
Apr 29, 2026

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational...

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
Apr 15, 2026

BEDFORD, Mass., April 15, 2026 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 3, 2026

BEDFORD, Mass., April 3, 2026 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention...

All Press Releases

Featured Event
Q1 2026 Anika Therapeutics Earnings Conference Call
Wednesday, April 29, 2026
8:30am - 9:30am EDT

See All Events

Current Investor Presentation

View PresentationView More
Investor Contacts

Primary IR Contact

  • Matt Hall

    Executive Director – Corporate Development & Investor Relations

    Anika Therapeutics, Inc.

    Phone: (781) 457-9554

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn, NY 11219

    Phone: (800) 937-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top